Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.Shares of Nektar Therapeutics (NKTR 0.08%), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly enthusiastic about recently announced clinical trial results for its lead candidate, rezpegaldesleukin.In a nutshell, it looks like it could become a top-selling treatment for eczema, an itchy autoimmune disorder that affects roughly 10% of ...